About the Company
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FULC News
Fulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical Officer
Fulcrum Therapeutics (NASDAQ:FULC) announces the appointment of Patrick Horn as chief medical officer, effective immediately. The interim Chief Medical Officer, Iain Fraser, will continue to serve on ...
Q4 2023 Fulcrum Therapeutics Inc Earnings Call
Matthew Biegler; Analyst; Oppenheimer & Co., Inc. Andrea Park; Analyst; Leerink Partners Dae Gon Ha; Analyst; Stifel Operator Good morning and welcome to Fulcrum Therapeutics Fourth Quarter and ...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
Feb. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the ...
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards ...
Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
?Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ? ?
Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript
Good morning and welcome to Fulcrum Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call. Currently all participants are in listen-only mode.
Fulcrum Therapeutics Inc FULC
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript
Fulcrum Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.44. FULC isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
Loading the latest forecasts...